MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer

Satoshi Fukagawa, Kohei Miyata, Fusanori Yotsumoto, Chihiro Kiyoshima, Sung Ouk Nam, Haruchika Anan, Takahiro Katsuda, Daisuke Miyahara, Masaharu Murata, Hiroshi Yagi, Kyoko Shirota, Shin'ichiro Yasunaga, Kiyoko Kato, Shingo Miyamoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.

Original languageEnglish
Pages (from-to)886-896
Number of pages11
JournalCancer Science
Volume108
Issue number5
DOIs
Publication statusPublished - May 2017

Fingerprint

MicroRNAs
Ovarian Neoplasms
Nucleic Acids
Biomarkers
Therapeutics
Ovarian Cysts
Serum
Heterografts
Antineoplastic Agents
Ovary
Neoplasms
Cell Proliferation
Polymerase Chain Reaction
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Fukagawa, S., Miyata, K., Yotsumoto, F., Kiyoshima, C., Nam, S. O., Anan, H., ... Miyamoto, S. (2017). MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Science, 108(5), 886-896. https://doi.org/10.1111/cas.13210

MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. / Fukagawa, Satoshi; Miyata, Kohei; Yotsumoto, Fusanori; Kiyoshima, Chihiro; Nam, Sung Ouk; Anan, Haruchika; Katsuda, Takahiro; Miyahara, Daisuke; Murata, Masaharu; Yagi, Hiroshi; Shirota, Kyoko; Yasunaga, Shin'ichiro; Kato, Kiyoko; Miyamoto, Shingo.

In: Cancer Science, Vol. 108, No. 5, 05.2017, p. 886-896.

Research output: Contribution to journalArticle

Fukagawa, S, Miyata, K, Yotsumoto, F, Kiyoshima, C, Nam, SO, Anan, H, Katsuda, T, Miyahara, D, Murata, M, Yagi, H, Shirota, K, Yasunaga, S, Kato, K & Miyamoto, S 2017, 'MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer', Cancer Science, vol. 108, no. 5, pp. 886-896. https://doi.org/10.1111/cas.13210
Fukagawa S, Miyata K, Yotsumoto F, Kiyoshima C, Nam SO, Anan H et al. MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Science. 2017 May;108(5):886-896. https://doi.org/10.1111/cas.13210
Fukagawa, Satoshi ; Miyata, Kohei ; Yotsumoto, Fusanori ; Kiyoshima, Chihiro ; Nam, Sung Ouk ; Anan, Haruchika ; Katsuda, Takahiro ; Miyahara, Daisuke ; Murata, Masaharu ; Yagi, Hiroshi ; Shirota, Kyoko ; Yasunaga, Shin'ichiro ; Kato, Kiyoko ; Miyamoto, Shingo. / MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. In: Cancer Science. 2017 ; Vol. 108, No. 5. pp. 886-896.
@article{352727938590408f9ef5b179889ab389,
title = "MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer",
abstract = "Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.",
author = "Satoshi Fukagawa and Kohei Miyata and Fusanori Yotsumoto and Chihiro Kiyoshima and Nam, {Sung Ouk} and Haruchika Anan and Takahiro Katsuda and Daisuke Miyahara and Masaharu Murata and Hiroshi Yagi and Kyoko Shirota and Shin'ichiro Yasunaga and Kiyoko Kato and Shingo Miyamoto",
year = "2017",
month = "5",
doi = "10.1111/cas.13210",
language = "English",
volume = "108",
pages = "886--896",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer

AU - Fukagawa, Satoshi

AU - Miyata, Kohei

AU - Yotsumoto, Fusanori

AU - Kiyoshima, Chihiro

AU - Nam, Sung Ouk

AU - Anan, Haruchika

AU - Katsuda, Takahiro

AU - Miyahara, Daisuke

AU - Murata, Masaharu

AU - Yagi, Hiroshi

AU - Shirota, Kyoko

AU - Yasunaga, Shin'ichiro

AU - Kato, Kiyoko

AU - Miyamoto, Shingo

PY - 2017/5

Y1 - 2017/5

N2 - Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.

AB - Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85019890760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019890760&partnerID=8YFLogxK

U2 - 10.1111/cas.13210

DO - 10.1111/cas.13210

M3 - Article

C2 - 28231414

AN - SCOPUS:85019890760

VL - 108

SP - 886

EP - 896

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 5

ER -